AMENDMENT NO. 1 TO DEVELOPMENT, COMMERCIALIZATION AND SUPPLY AGREEMENTDevelopment, Commercialization and Supply Agreement • November 7th, 2012 • Auxilium Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) is made as of November 6, 2012 (the “Amendment No. 1 Effective Date”) by and among Pfizer Inc., a Delaware corporation (“Pfizer”), Auxilium Pharmaceuticals, Inc., a Delaware corporation (“Auxilium Pharmaceuticals”) and Auxilium International Holdings, Inc., a Delaware corporation (“Auxilium International”, together with Auxilium Pharmaceuticals, “Auxilium”). Pfizer and Auxilium are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Auxilium and Pfizer Will Conclude Agreement on XIAPEX® EU CollaborationAuxilium and Pfizer Will • November 7th, 2012 • Auxilium Pharmaceuticals Inc • Pharmaceutical preparations
MALVERN, PA and NEW YORK, NY (November 7, 2012) — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, and Pfizer Inc. (NYSE: PFE) are amending their collaboration agreement for the development, commercialization and supply of XIAPEX in the European Union (EU) and certain other European and Eurasian countries (the “Collaboration Agreement”). As a result of this amendment, the Collaboration Agreement will terminate no later than April 24, 2013. Prior to the mutual termination date, the parties will continue to perform all of their obligations as described in the Collaboration Agreement. After the termination date, rights to commercialize XIAPEX and responsibility for regulatory activities for XIAPEX in these countries will revert to Auxilium.
